+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "T Cell Therapies"

From
From
From
From
CAR T-cell Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

CAR T-cell Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025 - Product Thumbnail Image

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 450 Pages
  • Global
From
Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 200 Pages
  • Global
From
Anti-CD30 Therapies - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD30 Therapies - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Anti-CD22 Therapies - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD22 Therapies - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
CAR T-Cell Therapy For Non-Hodgkin's Lymphoma- - Pipeline Insight, 2025 - Product Thumbnail Image

CAR T-Cell Therapy For Non-Hodgkin's Lymphoma- - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
From
CAR T-Cell Therapy For Multiple Myeloma - Pipeline Insight, 2025 - Product Thumbnail Image

CAR T-Cell Therapy For Multiple Myeloma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
NK Cell Therapies - Pipeline Insight, 2025 - Product Thumbnail Image

NK Cell Therapies - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
PI3K Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

PI3K Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 150 Pages
  • Global
From
4-1BB Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

4-1BB Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Cutaneous Squamous Cell Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Cutaneous Squamous Cell Carcinoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 120 Pages
  • Global
From
Hepatocellular Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatocellular Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 230 Pages
  • Global
From
Advanced Liver Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Liver Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2025 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 150 Pages
  • Global
From
Loading Indicator

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease. T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more